A股異動丨博騰股份(300363.SZ)漲4.45% 蘇州博騰擬引入外部投資者先進製造二期基金、高瓴辰鈞等等
格隆匯4月19日丨博騰股份(300363.SZ)漲4.45%,報55.59元,總市值302億元。博騰股份發佈公吿,將引入多個投資方共同對二級控股子公司——蘇州博騰生物製藥有限公司投資,促進基因細胞治療CDMO業務發展,滿足後續資本性支出及運營支出資金需求。投資者包括先進製造產業投資基金二期(有限合夥)、上海高瓴辰鈞股權投資合夥企業(有限合夥)等。博騰股份表示,本次蘇州博騰通過增資擴股方式引入外部投資者,有利於增強其資金實力和整體競爭力,促進公司基因細胞治療 CDMO 業務的發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.